Evidence map›Paper›PMID 23979944›Full record

ArticleG3 (Bethesda, Md.)2013

Targeted mutagenesis of Arabidopsis thaliana using engineered TAL effector nucleases.

Michelle Christian, Yiping Qi, Yong Zhang, Daniel F Voytas

Abstract read
In one paragraph

Article in G3 (Bethesda, Md.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed.

  1. Review
  2. Review
  3. CRISPR/Cas9-mediated genome editing technique to control fall armyworm (Physiology and molecular biology of plants : an international journal of functional plant biology · 2024
    Review
  4. Review
  5. Review
  6. Maize transformation: history, progress, and perspectives.Molecular breeding : new strategies in plant improvement · 2021
    Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Michelle ChristianDepartment of Genetics, Cell Biology, and Development and Center for Genome Engineering, University of Minnesota, Minneapolis, Minnesota 55455.
Yiping Qi
Yong Zhang
Daniel F Voytas

Funding

DNA targeting by TAL effectorsR01GM098861 · NIGMS · IOWA STATE UNIVERSITY · PI BOGDANOVE, ADAM J, STODDARD, BARRY L. · 2011 to 2014
$2.0M
NIGMS NIH HHS R01 GM098861
6 · The paper itself

Abstract

Custom TAL effector nucleases (TALENs) are increasingly used as reagents to manipulate genomes in vivo. Here, we used TALENs to modify the genome of the model plant, Arabidopsis thaliana. We engineered seven TALENs targeting five Arabidopsis genes, namely ADH1, TT4, MAPKKK1, DSK2B, and NATA2. In pooled seedlings expressing the TALENs, we observed somatic mutagenesis frequencies ranging from 2-15% at the intended targets for all seven TALENs. Somatic mutagenesis frequencies as high as 41-73% were observed in individual transgenic plant lines expressing the TALENs. Additionally, a TALEN pair targeting a tandemly duplicated gene induced a 4.4-kb deletion in somatic cells. For the most active TALEN pairs, namely those targeting ADH1 and NATA2, we found that TALEN-induced mutations were transmitted to the next generation at frequencies of 1.5-12%. Our work demonstrates that TALENs are useful reagents for achieving targeted mutagenesis in this important plant model.

Indexed as

Amino Acid SequenceArabidopsisBase SequenceDNA Restriction EnzymesGenes, PlantGene TargetingMolecular Sequence DataMutagenesis, Site-DirectedPlants, Genetically ModifiedDNA Restriction EnzymesArabidopsis thaliananonhomologous end-joiningTAL effector nucleasetargeted mutagenesis

Identifiers

PMID23979944
PMCPMC3789794

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.